PMID- 35094518
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220323
IS  - 1944-8252 (Electronic)
IS  - 1944-8244 (Linking)
VI  - 14
IP  - 5
DP  - 2022 Feb 9
TI  - Biomineralized Cascade Enzyme-Encapsulated ZIF-8 Nanoparticles Combined with 
      Antisense Oligonucleotides for Drug-Resistant Bacteria Treatment.
PG  - 6453-6464
LID - 10.1021/acsami.1c23808 [doi]
AB  - The unrestrained use of antibiotics accelerates the development of drug-resistant 
      bacteria and leads to an increasing threat to human health. Therefore, there is 
      an urgent need to explore novel and effective strategies for the treatment of 
      bacterial infections. Herein, zeolite imidazole framework-8 (ZIF-8) material was 
      utilized to construct biomineralized nanomaterial (GOx&HRP@ZIF-8/ASO) by 
      encapsulating biological cascade enzymes and combining with antisense 
      oligonucleotides (ASOs), which achieved effective and synergistic 
      antidrug-resistant bacteria therapy. Various in vitro assays confirmed that 
      GOx&HRP@ZIF-8/ASO exhibited excellent antibacterial properties against 
      Escherichia coli, Staphylococcus aureus, methicillin-resistant S. aureus (MRSA) 
      during catalysis of glucose (Glu), especially the minimum inhibitory 
      concentration (MIC) against MRSA was only 16 mug/mL. Compared with simple ZIF-8 
      (32.85%) and ftsZ ASO (58.65%), GOx&HRP@ZIF-8/ASO+Glu exhibited superb biofilm 
      destruction ability, and the bacteria removal efficiency of the MRSA biofilm 
      could be as high as 88.2%, indicating that the reactive oxygen species (ROS) 
      produced by the cascade enzyme reaction imparted the main synergistic 
      antibacterial capability, and simultaneously, ftsZ ASO significantly enhanced the 
      antibacterial effect by inhibiting the expression of the ftsZ gene. In vivo 
      anti-infection treatment experiments revealed that GOx&HRP@ZIF-8/ASO exhibited 
      the best wound repairing performance and excellent biocompatibility in the 
      presence of Glu. These findings suggested that GOx&HRP@ZIF-8/ASO has favorably 
      realized high-efficiency treatment of MRSA infection and filled the gap in the 
      antibacterial application of biological enzymes.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Lai, Luogen
AU  - Lai L
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Liu, Yijun
AU  - Liu Y
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Chen, Beini
AU  - Chen B
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Yao, Jing
AU  - Yao J
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Zheng, Pengwu
AU  - Zheng P
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Pan, Qingshan
AU  - Pan Q
AUID- ORCID: 0000-0002-2652-1563
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
FAU - Zhu, Wufu
AU  - Zhu W
AUID- ORCID: 0000-0001-6075-0450
AD  - Jiangxi Provincial Key Laboratory of Drug Design and Evaluation, School of 
      Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, 
      Jiangxi, China.
LA  - eng
PT  - Journal Article
DEP - 20220130
PL  - United States
TA  - ACS Appl Mater Interfaces
JT  - ACS applied materials & interfaces
JID - 101504991
RN  - 0 (Bacterial Proteins)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (FtsZ protein, Bacteria)
RN  - 0 (Imidazoles)
RN  - 0 (Metal-Organic Frameworks)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (ZIF-8 metal-organic framework)
RN  - 3352-57-6 (Hydroxyl Radical)
RN  - EC 1.1.3.4 (Glucose Oxidase)
RN  - EC 1.11.1.- (Horseradish Peroxidase)
SB  - IM
MH  - Animals
MH  - Bacterial Proteins/antagonists & inhibitors/genetics/metabolism
MH  - Biofilms/drug effects
MH  - Cytoskeletal Proteins/antagonists & inhibitors/genetics/metabolism
MH  - Escherichia coli/drug effects
MH  - Glucose Oxidase/*chemistry/metabolism
MH  - Horseradish Peroxidase/*chemistry/metabolism
MH  - Hydroxyl Radical/metabolism
MH  - Imidazoles/*chemistry/pharmacology
MH  - Metal-Organic Frameworks/*chemistry/pharmacology
MH  - Methicillin-Resistant Staphylococcus aureus/drug effects/physiology
MH  - Mice
MH  - Microbial Sensitivity Tests
MH  - Nanoparticles/*chemistry/therapeutic use/toxicity
MH  - Oligonucleotides, Antisense/*chemistry/metabolism/pharmacology
MH  - Reactive Oxygen Species/metabolism
MH  - Skin Diseases/drug therapy/pathology/veterinary
MH  - Staphylococcal Infections/drug therapy/veterinary
MH  - Staphylococcus aureus/drug effects
OTO - NOTNLM
OT  - antisense oligonucleotides
OT  - biomineralized nanomaterial
OT  - cascade enzymes
OT  - synergistic antibacterial therapy
OT  - zeolite imidazolate framework-8
EDAT- 2022/02/01 06:00
MHDA- 2022/03/24 06:00
CRDT- 2022/01/31 05:33
PHST- 2022/02/01 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2022/01/31 05:33 [entrez]
AID - 10.1021/acsami.1c23808 [doi]
PST - ppublish
SO  - ACS Appl Mater Interfaces. 2022 Feb 9;14(5):6453-6464. doi: 
      10.1021/acsami.1c23808. Epub 2022 Jan 30.